Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1-style safety, PK, and PD study of intravenous DMT and deuterated DMT (CYB004) in healthy smokers and non-smokers
NL-OMON54291Phase 1Active, not recruiting
- Sponsor
- Cybin Inc.
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of HLP004 and DMT in nicotine dependence, affective disorder and anxiety disorder (5 arms), sponsored by Cybin Inc. Started Feb 2022; status: active, not recruiting.
02
Drugs
HLP004DMT
03
Conditions
nicotine dependenceaffective disorderanxiety disorder
Beyond the preview
Go deeper on NL-OMON54291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54291.